Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status
Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…